SII

Serum Institute of India (SII) is confident of getting approval for Covishield from European Medicines Agency (EMA) within a month. SII’s CEO Adar Poonawalla also said that the issue of vaccine passports should be on the basis of…

Pune: The Serum Institute of India (SII) announced on Friday that his company has manufactured the first batch of the Covavax COVID-19 vaccine, which has been developed by US-based biotechnology company Novavax. “Excited to witness the…

New Delhi: Serum Institute of India (SII) is expected to begin clinical trials of Novavax’s COVID-19 vaccine ‘Covovax’ for children this July, according to media reports. SII is also planning to introduce Covovax in India by September.…

New Delhi: Covishield-maker Serum Institute of India (SII) has sought indemnity from liability or legal protection from any claims linked any severe side effects from the company’s COVID-19 vaccine. Notably, foreign vaccine-makers Pfizer…

New Delhi: Executive Director of Pune-based Serum Institute of India (SII) Suresh Jadhav on Friday alleged that the government began inoculating people from multiple age groups without taking into account the available stock of vaccines and…

New Delhi: Serum Institute of India (SII) CEO Adar Poonawalla on Tuesday said vaccines were never exported at the cost of people of India, adding that there were commitments to Covax as well that had to be met so that doses could be…

Pune: The Serum Institute of India (SII) on Saturday said that only a limited portion of its volume of Covidshield will be sold to private hospitals at Rs 600 per dose. "The price of the vaccine is still lower than a lot of other medical…

New Delhi: COVID-19 vaccine manufacturers Bharat Biotech and Serum Institute of India (SII) will get Rs 1,500 crore and Rs 3,000 crore each as supply credit from the Finance Ministry. The Ministry, which gave an in-principle nod for the…

New Delhi: The Serum Institute of India (SII) has geared up to raise the output of Covishield vaccines by 67% to 100 million doses a month from May. The move comes in the backdrop of the increasing demand for vaccines in view of the fast…

New Delhi: The CEO of Serum Institute of India (SII), Adar Poonawalla, on Sunday urged nations to “be patient” amid the wait for Covishield, the COVID-19 vaccine developed by SII in partnership with Oxford University and pharmaceutical…